Evidence map›Paper›PMID 24348510›Full record

ReviewFrontiers in genetics2013

Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells.

Farnaz Faridi, Kanagaraju Ponnusamy, Isabell Quagliano-Lo Coco, Linping Chen-Wichmann, Manuel Grez, Reinhard Henschler, Christian Wichmann

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Farnaz FaridiDepartment of Transfusion Medicine, Cell Therapeutics and Hemostasis, Ludwig-Maximilian University Hospital Munich, Germany.
Kanagaraju PonnusamyDepartment of Transfusion Medicine, Cell Therapeutics and Hemostasis, Ludwig-Maximilian University Hospital Munich, Germany ; Institute of Transfusion Medicine and Immunohematology, Goethe University Frankfurt, Germany.
Isabell Quagliano-Lo CocoInstitute for Biomedical Research Georg-Speyer-Haus, Frankfurt, Germany.
Linping Chen-WichmannDepartment of Transfusion Medicine, Cell Therapeutics and Hemostasis, Ludwig-Maximilian University Hospital Munich, Germany.
Manuel GrezInstitute for Biomedical Research Georg-Speyer-Haus, Frankfurt, Germany.
Reinhard HenschlerDepartment of Transfusion Medicine, Cell Therapeutics and Hemostasis, Ludwig-Maximilian University Hospital Munich, Germany.
Christian WichmannDepartment of Transfusion Medicine, Cell Therapeutics and Hemostasis, Ludwig-Maximilian University Hospital Munich, Germany.
Ludwig-Maximilians-Universität München · DEGeorg Speyer Haus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription is a tightly regulated process ensuring the proper expression of numerous genes regulating all aspects of cellular behavior. Transcription factors regulate multiple genes including other transcription factors that together control a highly complex gene network. The transcriptional machinery can be "hijacked" by oncogenic transcription factors, thereby leading to malignant cell transformation. Oncogenic transcription factors manipulate a variety of epigenetic control mechanisms to fulfill gene regulatory and cell transforming functions. These factors assemble epigenetic regulators at target gene promoter sequences, thereby disturbing physiological gene expression patterns. Retroviral vector technology and the availability of "healthy" human hematopoietic CD34+ progenitor cells enable the generation of pre-leukemic cell models for the analysis of aberrant human hematopoietic progenitor cell expansion mediated by leukemogenic transcription factors. This review summarizes recent findings regarding the mechanism by which leukemogenic gene products control human hematopoietic CD34+ progenitor cell expansion by disrupting the normal epigenetic program.

Indexed as

epigeneticsHSPCleukemiaRUNX1/ETOstem/progenitor cell expansion

Identifiers

PMID24348510
PMCPMC3842847
OpenAlexW2104327186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.